Development of new treatments with RAGE-aptamer-incorporated nanoparticles for pulmonary arterial hypertension
| Project/Area Number |
18K08037
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Review Section |
Basic Section 53020:Cardiology-related
|
|---|
| Research Institution | Okayama University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
赤木 達 岡山大学, 医歯薬学総合研究科, 助教 (60601127)
阪口 政清 岡山大学, 医歯薬学総合研究科, 教授 (70379840)
三好 亨 岡山大学, 大学病院, 講師 (70444651)
深水 圭 久留米大学, 医学部, 教授 (80309781)
伊藤 浩 岡山大学, 医歯薬学総合研究科, 教授 (90446047)
|
|---|
| Project Period (FY) |
2018-04-01 – 2021-03-31
|
| Project Status |
Completed (Fiscal Year 2020)
|
| Budget Amount *help |
¥4,420,000 (Direct Cost: ¥3,400,000、Indirect Cost: ¥1,020,000)
Fiscal Year 2020: ¥520,000 (Direct Cost: ¥400,000、Indirect Cost: ¥120,000)
Fiscal Year 2019: ¥2,080,000 (Direct Cost: ¥1,600,000、Indirect Cost: ¥480,000)
Fiscal Year 2018: ¥1,820,000 (Direct Cost: ¥1,400,000、Indirect Cost: ¥420,000)
|
|---|
| Keywords | 肺高血圧症 / 終末糖化産物受容体 / RAGE / 血小板由来増殖因子 / 肺動脈平滑筋細胞 / S100A8/A9蛋白 / DNA-aptamer / モノクロタリン誘発性肺高血圧症 / S100蛋白 / 細胞増殖 / 肺動脈性肺高血圧症 / RAGE-aptamer / ナノ粒子 / 血管リモデリング |
|---|
| Outline of Final Research Achievements |
1.Inhibitory effects of RAGE-aptamer on development of monocrotaline-induced pulmonary arterial hypertension in rats.: Continuous subcutaneous delivery of RAGE-aptamer suppresses development of monocrotaline-induced PAH in rats. Inhibition of RAGE ameliorates muscularization of small pulmonary arteries. Treatment with RAGE-aptamer might be a new therapeutic option for pulmonary arterial hypertension (PAH).
2.Inhibitory effects of RAGE-aptamer on proliferation of pulmonary artery smooth muscle cells (PASMCs) from patients with PAH: RAGE plays a crucial role in the inappropriate increase of PAH-PASMCs. Inhibition of RAGE signaling using RAGE aptamer inhibited the inappropriate increase of PAH-PASMCs.
|
| Academic Significance and Societal Importance of the Research Achievements |
我々を含めRAGEシグナルがPAHの病態に関与すると報告しているがRAGEシグナル抑制による治療法はまだ開発されていない。今回肺高血圧症にてRAGE特異的 DNA aptamerの有効性をしめし、RAGEシグナル抑制という世界初の治療法の開発につながる研究である。将来的に患者の予後改善・QOLの向上にもつながる日本発の治療法として発展することを期待される。
|
Report
(4 results)
Research Products
(36 results)
-
-
-
-
-
-
-
-
-
[Journal Article] Role of smooth muscle cell p53 in pulmonary arterial hypertension2019
Author(s)
Wakasugi Takayuki、Shimizu Ippei、Yoshida Yohko、Hayashi Yuka、Ikegami Ryutaro、Suda Masayoshi、Katsuumi Goro、Nakao Masaaki、Hoyano Makoto、Kashimura Takeshi、Nakamura Kazufumi、Ito Hiroshi、Nojiri Takashi、Soga Tomoyoshi、Minamino Tohru
-
Journal Title
PLOS ONE
Volume: 14
Issue: 2
Pages: e0212889-e0212889
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
[Journal Article] Crucial role of rage in inappropriate increase of smooth muscle cells from patients with pulmonary arterial hypertension.2018
Author(s)
Nakamura K, Sakaguchi M, Matsubara H, Akagi S, Sarashina T, Ejiri K, Akazawa K, Kondo M, Nakagawa K, Yoshida M, Miyoshi T, Ogo T, Oto T, Toyooka S, Higashimoto Y, Fukami K, Ito H.
-
Journal Title
PLoS One
Volume: 13
Issue: 9
Pages: 1-11
DOI
Related Report
Peer Reviewed / Open Access
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
-
